Introduction
API Holdings, the parent company behind PharmEasy, has emerged as one of India’s most valuable startups in the healthcare sector. As investors look beyond the stock market for new opportunities, API unlisted shares have gained significant traction among those betting on the future of digital healthcare and e-pharmacy in India. Here’s a deep dive into its price trend, market sentiment, and long-term outlook.
About API Holdings
API Holdings is the holding company of PharmEasy, one of India’s largest digital healthcare platforms offering teleconsultations, lab tests, and medicine delivery. Founded in 2015, PharmEasy has grown exponentially, serving millions of users and partnering with thousands of pharmacies and diagnostic centers across the country.
Its focus on tech-driven healthcare and seamless digital solutions has positioned API Holdings as a strong pre-IPO candidate in India’s fast-evolving healthcare market.
API Unlisted Share Price (2025 Update)
As of early 2025, the API unlisted share price is trading around ₹80–₹90 per share in the unlisted market. The price has shown a modest recovery after a dip in 2023, driven by improved performance and positive signals from the broader healthcare sector.
Note: Unlisted share prices fluctuate based on demand, liquidity, and company performance. Always refer to reliable sources like Delisted Stocks for updated data.
Reasons Why Investors Are Tracking API Unlisted Shares
The growing investor interest in API Holdings comes from multiple strong factors:
India’s Growing Healthcare Demand: With rising digital adoption and online medicine orders, API is well-positioned for exponential growth.
Pre-IPO Opportunity: API is considered a potential IPO candidate in the coming years, making it a preferred pick for early-stage investors.
Diverse Revenue Streams: Beyond medicine delivery, API also earns from diagnostics, teleconsultation, and B2B pharma solutions.
Post-COVID Digital Boom: The pandemic accelerated the adoption of online healthcare, creating long-term demand for API’s services.
These growth drivers make API unlisted shares an attractive long-term bet for investors who understand the potential of the digital health ecosystem.
Financial & Market Overview
API Holdings reported strong revenue growth in FY2024–25, backed by higher order volumes, better unit economics, and expansion into Tier 2 and Tier 3 cities. The company’s focus on tech efficiency, cost reduction, and acquisitions of smaller diagnostic startups has strengthened its market position.
Even though API reported minor losses due to scaling efforts, its long-term fundamentals remain solid, supported by rising market share in India’s e-health sector.
How to Buy API Unlisted Shares
Investing in API unlisted shares is easy for investors seeking pre-IPO opportunities. Here’s how you can do it:
Get in touch with an authorized unlisted share dealer.
Complete KYC and payment formalities.
Receive shares directly in your Demat account.
For the latest API unlisted share price or to buy in bulk, visit reliable platforms like Delisted Stocks where verified listings are regularly updated.
Expert Investment Outlook (2025)
Financial analysts believe that API Holdings will continue to grow as India’s healthcare infrastructure evolves. With more users switching to digital platforms for consultations, prescriptions, and diagnostics, API’s business model is future-ready.
If the company maintains consistent revenue growth and improves profitability, API unlisted shares could deliver strong returns once the IPO is announced.
Conclusion
The API unlisted share represents a unique opportunity for investors looking to participate in India’s healthcare revolution before it reaches the public market. Its consistent growth, robust business model, and digital-first strategy make it one of the most followed unlisted stocks in 2025.
Before investing, always verify the latest unlisted share prices and trends through trusted sources like Delisted Stocks to ensure accuracy and transparency.